Cytokinetics Inc
Company Profile
Business description
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Contact
350 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 624-3000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
673
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.20 | 113.70 | 1.29% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,367.08 | 1,638.36 | 3.11% |
| NZX 50 Index | 13,196.36 | 97.53 | 0.74% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,728.70 | 126.40 | 1.47% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |